Report: Current Stock Reports

Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update
December 11, 2023

Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting
December 11, 2023

Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023
December 7, 2023

Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting
November 2, 2023

Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update
October 23, 2023

Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes
October 20, 2023

RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023
October 16, 2023

Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 16, 2023

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 4, 2023

Conclusion of an amendment to global License Agreement with Menarini Group
September 14, 2023

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
August 4, 2023

Conclusion of a financing agreement with the Medical Research Agency
July 31, 2023

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
July 31, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
July 21, 2023

Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
July 14, 2023

Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
July 6, 2023

Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
June 19, 2023

Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
June 14, 2023

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
June 14, 2023

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
June 14, 2023